Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment...